Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Enhanced YB1/EphA2 Axis Signaling Promotes Acquired Resistance to Sunitinib and Metastatic Potential in RCC
  2. Immune Profiling of Papillary Renal Cell Carcinoma
  3. Partial Nephrectomy Preserves Renal Function Without Increasing the Risk of Complications for Stage pT2–3a RCC
  4. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Sunitinib in First-Line Treatment of Advanced Sarcomatoid RCC
  5. Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Non-Metastatic RCC
  6. Impact of TKIs Combined With Radiation Therapy for the Management of Brain Metastases From RCC
  7. Stool Microbiome Profiling of Patients With Metastatic RCC Receiving Anti–PD-1 Immune Checkpoint Inhibitors
  8. ESMO 2020: Recommendations From Dr. Jun Gong for Genitourinary Cancer
  9. ESMO 2020: Recommendations From Dr. Jun Gong for Gastrointestinal Cancer
  10. Predictive Ability for Disease-Free Survival of the GRANT Score in Patients With Resected RCC

Elsewhere

Recently Updated